QUIDEL CORP (US2197981051) QuidelOrtho to Participate in the Raymond James...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho Receives De Novo FDA Authorization for...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho Announces the Formation of the...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho Reports Preliminary Revenue Results...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho Reports First Quarter 2023 Financial...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho to Participate in William Blair 43rd...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho to Report Second Quarter 2023...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho Partners With BYG4lab® to Strengthen...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho Ranks No. 1 in Customer Satisfaction...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho Reports Second Quarter 2023 Financial...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho to Participate in the Morgan Stanley...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho Receives CLIA Waiver for Sofia® 2 SARS...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho Reports Preliminary Revenue Results...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho Reports Third Quarter 2023 Financial...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho to Participate in the Evercore ISI...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho Receives 510(K) Clearance for Savanna®...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho to Present at 42nd Annual J.P. Morgan...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (NASDAQ:QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho to Report Fourth Quarter and Full-year...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho Reports Fourth Quarter and Full-Year...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho Announces Changes in Executive Leadership
SAN DIEGO--(BUSINESS WIRE)-- The Board of Directors (the “Board”) of QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”) has made significant decisions aimed to enhance operational...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho to Participate in 45th Annual Raymond...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho Receives Health Canada Approval for...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq:QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho Receives FDA 510(k) Clearance for Its...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho\" or the “Company”) has received U.S. Food and Drug Administration (“FDA”) 510(k) clearance for its QuickVue COVID-19...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho Adds Fentanyl Test to Its Vitros®...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) has added the ARK™ Fentanyl II Assay to its U.S. Vitros® XT 7600 and 5600 Integrated Systems as well as its Vitros® 4600 Chemistry...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho To Report First Quarter 2024 Financial...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care...
View Article
